Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 02, 2013 06:00 ET | Source: Astex Pharmaceuticals, Inc.

Astex Pharmaceuticals Announces Initiation of SGI-110 Phase 2 Trial in Advanced Hepatocellular Carcinoma (HCC) Patients

DUBLIN, Calif., Jan. 2, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics,...
December 10, 2012 12:12 ET | Source: Astex Pharmaceuticals, Inc.

Astex Pharmaceuticals Announces Results From Dose Escalation Part of SGI-110 Phase 1/2 MDS and AML Study in an Oral Presentation at ASH

DUBLIN, Calif., Dec. 10, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics,...
December 05, 2012 06:00 ET | Source: Astex Pharmaceuticals, Inc.

Astex Pharmaceuticals to Present at Oppenheimer Healthcare Conference

DUBLIN, Calif., Dec. 5, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics,...
December 04, 2012 06:00 ET | Source: Astex Pharmaceuticals, Inc.

Astex Pharmaceuticals Announces December 14th Analyst and Investor Day Agenda

DUBLIN, Calif., Dec. 4, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics,...
November 20, 2012 06:00 ET | Source: Astex Pharmaceuticals, Inc.

Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Results From Phase 1/2 MDS and AML Study at ASH

DUBLIN, Calif., Nov. 20, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics,...
November 07, 2012 06:00 ET | Source: Astex Pharmaceuticals, Inc.

Astex Pharmaceuticals to Present at Lazard Healthcare Conference

DUBLIN, Calif., Nov. 7, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics,...
October 31, 2012 06:00 ET | Source: Astex Pharmaceuticals, Inc.

Astex Pharmaceuticals to Present at EORTC-NCI-AACR

DUBLIN, Calif., Oct. 31, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics,...
October 30, 2012 16:00 ET | Source: Astex Pharmaceuticals, Inc.

Astex Pharmaceuticals Reports 2012 Third Quarter Financial Results

Dacogen Approved in the European Union for the Treatment of Elderly AML Initiated HSP90 Inhibitor AT13387 Clinical Trials in Prostate & Lung Cancer Patients Initiated SGI-110 Clinical Trial...
October 29, 2012 09:59 ET | Source: Astex Pharmaceuticals, Inc.

Astex Pharmaceuticals, Cancer Research Technology and Newcastle University Sign Strategic Drug Discovery Alliance

DUBLIN, Calif. and CAMBRIDGE, U.K., Oct. 29, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small...
October 24, 2012 06:00 ET | Source: Astex Pharmaceuticals, Inc.

Astex Pharmaceuticals Announces Initiation of AT13387 Phase 2 Study in Non-Small Cell Lung Cancer

DUBLIN, Calif., Oct. 24, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right